The two-year project ‘drug discovery for bone and joint protection: structural biology for novel targets and their inhibitors’ focuses on Galapagos’s novel drug targets and the candidate drugs that bind to these targets.
This information will help Galapagos to design potent and selective drugs and thus potentially improve their efficacy to treat bone and joint diseases. Galapagos will collaborate on this project with the Structural Biology Brussels group at the Flanders Institute for Biotechnology (VIB).
Graham Dixon, senior vice president of drug discovery at Galapagos, said: “This grant gives us an opportunity to collaborate with the VIB’s top structural biology group, thereby adding to our drug discovery capabilities. Through this research we aim to progress our understanding of these novel drug targets and accelerate the development of candidate drugs for bone and joint diseases.”